New obesity drug AMG 133 enters human safety testing

NCT ID NCT04478708

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested a new drug called maridebart cafraglutide (AMG 133) in 110 adults with obesity. The main goal was to see if the drug is safe and tolerable when given as a single dose or multiple doses. Researchers also measured how the drug moves through the body. This study does not yet test whether the drug helps with weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: maridebart cafraglutide (AMG 133)
What this could lead to: If successful, this could point toward a new weight-loss treatment for obesity.
What could go wrong: This is an early Phase 1 trial focused on safety, not weight loss. It is small and may not lead to an effective treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Anaheim Clinical Trials

Anaheim, California, 92801, United States
Clinical Pharmacology of Miami, LLC

Miami, Florida, 33014, United States
Orange County Research Center

Tustin, California, 92780, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.